We apply our proprietary AP3 patient selection platform to develop targeted cancer therapies with high probability of clinical success. Our clinical pipeline is focused on advanced assets targeting the DNA Damage Response (DDR) and cell cycle regulation with demonstrated, durable single agent activity in major tumors but where traditional patient selection is challenging. Likewise, our preclinical drug programs are against DDR targets with no obvious genetic patient selection path. Our OncoSignature® patient selection method will be used for patient responder enrichment to enable successful clinical development.
Acrivon Pipeline
Acrivon’s Lead Program ACR-368 (also known as Prexasertib, in-licensed from Lilly), is a clinically-advanced, second-generation inhibitor of the DNA Damage Response checkpoint kinases, CHK1 and CHK2. ACR-368 has demonstrated durable monotherapy activity, including complete responses, in a proportion of patients with platinum-resistant ovarian cancer* and squamous cell cancer ‡. Using OncoSignature®, we have identified endometrial and bladder cancer as two additional high unmet need solid tumor types predicted to be highly sensitive to the drug. Our two drug discovery programs target critical regulators of the DNA Damage Response and the cell cycle.
*Ref: Lee et al, Lancet Oncology (2018); ‡ Ref: Hong et al, CCR (2018)
Discovery
Preclinical
Phase 1
Phase 2
Registrational
ACR-368 (CHK1/CHK2)
Platinum-Resistant Ovarian Cancer
Platinum-Resistant Endometrial Cancer
Platinum-Resistant Bladder Cancer
Anal Cancer (ODD)# ^
Head and Neck Cancer^
Additional Solid Tumor Type^ †
Discovery Program 1 (DDR)
Discovery Program 2 (DDR)
◆
Phase 2 trial (master protocol) to treat patients based on OncoSignature® -predicted ACR-368 sensitivity
#
ACR-368 granted Orphan Drug Designation for the treatment of Anal Cancer
^
Staggered development planned under master protocol
†
Identified to be sensitive to ACR-368 by OncoSignature® screening, not previously treated with the drug
